ORIC
HEALTHCAREORIC Pharmaceuticals Inc
$9.30-0.27 (-2.82%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ORIC Today?
No stock-specific AI insight has been generated for ORIC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.54$14.93
$9.30
Fundamentals
Market Cap$963M
P/E Ratio—
EPS$-1.39
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding103.5M
ORIC News
21 articles- ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational UpdatesYahoo Finance·May 4, 2026
- ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual MeetingYahoo Finance·Apr 17, 2026
- A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer DataYahoo Finance·Apr 6, 2026
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJMBiopharmadive·Apr 2, 2026
- ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3Yahoo Finance·Apr 2, 2026
- Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And PlungesYahoo Finance·Apr 1, 2026
- Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait OpenedYahoo Finance·Apr 1, 2026
- ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?Benzinga·Apr 1, 2026
- Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 TrialMarketbeat·Mar 31, 2026
- ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease ProfileYahoo Finance·Mar 31, 2026
- ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPCYahoo Finance·Mar 27, 2026
- Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.Motley Fool·Mar 19, 2026
- ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual MeetingYahoo Finance·Mar 17, 2026
- Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety ConcernsYahoo Finance·Mar 13, 2026
- A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price VolatilityYahoo Finance·Mar 13, 2026
- Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained247 Wall St·Mar 10, 2026
- After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is BrightYahoo Finance·Mar 9, 2026
- Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer DrugsMarketbeat·Mar 1, 2026
- Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to TradeYahoo Finance·Feb 26, 2026
- Oric Pharmaceuticals price target raised to $25 from $23 at H.C. WainwrightYahoo Finance·Feb 25, 2026
All 21 articles loaded
Price Data
Open$9.67
Previous Close$9.57
Day High$9.67
Day Low$9.15
52 Week High$14.93
52 Week Low$4.54
52-Week Range
$4.54$14.93
$9.30
Fundamentals
Market Cap$963M
P/E Ratio—
EPS$-1.39
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding103.5M
About ORIC Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—